Journal: bioRxiv

Article Title: Resveratrol attenuates high-fat diet-induced obesity and the aging-related sarcopenia mitochondrial dysfunction in skeletal muscle

doi: 10.1101/823088

Figure Lengend Snippet: Resveratrol reduces matrix metalloproteinases in skeletal muscles of obesity-induced sarcopenia, but elevates matrix metalloproteinases in age-related sarcopenia SAMP8 mice. (A). The levels of MMP2, MMP9, ANP, and BNP protein in high-fat diet (HFD)-induced obesity were measured by western blotting. All data is expressed mean ± SEM. * p <0.05, ** p <0.01, significant difference compared with control. # p <0.05, significant difference compared with HFD mice without treatment. α-tubulin was used as a loading control. HFD: High-fat diet; LR: Low–dose resveratrol; MR: Middle–dose resveratrol; HR: High–dose resveratrol. (B). Western blot analysis of MMP2, MMP9, FGF-2, and UPA were performed in sarcopenia SAMP8 mice. α-tubulin was used as a loading control. Quantification of Western blot bands by densitometry. All data are expressed as mean ± SEM. * p <0.05, ** p <0.01, significant difference compared with SAMP8 mice without treatment. NS. was no significant difference. SAMP8; SAMP8 control groups, SAMP8+Ex; exercise training SAMP8 groups, SAMP8+ Re; resveratrol intake SAMP8 groups, SAMP8+Ex+Re; combination exercise training and resveratrol intake SAMP8 groups.

Article Snippet: Western blot analysis was performed as previously described (Sibilia et al., 2000) with antibodies detecting ANP, BNP, FGF-2, UPA, PI3K, AKT, IL-6, STAT3, p-JNK, p-P38, and tubulin (Santa Cruz).

Techniques: Western Blot

Journal: International Journal of Biological Sciences

Article Title: Screening of an FDA-approved compound library identifies apigenin for the treatment of myocardial injury

doi: 10.7150/ijbs.85204

Figure Lengend Snippet: Apigenin attenuates Dox-mediated myocardial injury. Mice were treated with Dox (15 mg/kg) with or without oral apigenin co-administration (25 mg/kg) for 4 weeks. (A-C) Serum was isolated from mice and the levels of TnT, BNP, and CK-MB were measured through ELISA. (D) Sirius Red staining was used to observe histological alterations in heart tissue. (E , F) GR-1 immunofluorescence was used to evaluate neutrophil infiltration in the myocardium. (G-H) The transcription of IL-6 and MMP9 in heart tissues was assessed by RT-PCR. *p<0.05.

Article Snippet: The following ELISA kits were used: ATP concentration (LS-F24998, LifeSpan BioSciences), serum Troponin T (TNT) concentration (abx496644, Abbexa), serum BNP concentration (NBP2-70011, Novus), serum CK-MB concentration (NBP2-75312, Novus), Gpx activity (ab102530, Abcam), Prx3 activity (ab277720, Abcam), and Txnrd2 activity (MBS9328396, MybioSource) .

Techniques: Isolation, Enzyme-linked Immunosorbent Assay, Staining, Immunofluorescence, Reverse Transcription Polymerase Chain Reaction

Journal: International Journal of Biological Sciences

Article Title: Screening of an FDA-approved compound library identifies apigenin for the treatment of myocardial injury

doi: 10.7150/ijbs.85204

Figure Lengend Snippet: Sirt1 knockdown abolishes the cardioprotective effects of apigenin in mice with Dox-induced cardiomyopathy. Wild-type (WT) and Sirt1 knockout (KO) mice were treated with Dox (15 mg/kg) with or without concomitant oral apigenin (25 mg/kg) administration for 4 weeks. (A-C) Serum levels of TnT, BNP, and CK-MB were measured by ELISA. (D) Sirius Red staining was used to observe histological alterations in heart tissue. (E , F) GR-1 immunofluorescence was used to assess neutrophil infiltration in the myocardium. (G-H) RT-PCR was used to analyze the transcription of IL-6, MCP1, and MMP9 in heart tissues. *p<0.05.

Article Snippet: The following ELISA kits were used: ATP concentration (LS-F24998, LifeSpan BioSciences), serum Troponin T (TNT) concentration (abx496644, Abbexa), serum BNP concentration (NBP2-70011, Novus), serum CK-MB concentration (NBP2-75312, Novus), Gpx activity (ab102530, Abcam), Prx3 activity (ab277720, Abcam), and Txnrd2 activity (MBS9328396, MybioSource) .

Techniques: Knockdown, Knock-Out, Enzyme-linked Immunosorbent Assay, Staining, Immunofluorescence, Reverse Transcription Polymerase Chain Reaction

Journal: Journal of inherited metabolic disease

Article Title: Slc22a5 haploinsufficiency does not aggravate the phenotype of the long-chain acyl-CoA dehydrogenase KO mouse

doi: 10.1002/jimd.12204

Figure Lengend Snippet: Characterization of LCAD KO phenotypes in Slc22a5jvs/+ Acadl−/− mice. (A) Individual values and the average for blood glucose, liver weight, heart weight and heart water content are graphed for males and females separately. The result of the 2way ANOVA is displayed within the graph: I denotes the significance of the interaction term, S denotes the significance of the effect of sex and G denotes the significance of the effect of genotype. The results of Sidak’s multiple comparisons test is only displayed if the difference between Slc22a5jvs/+ Acadl−/− and Slc22a5+/+ Acadl−/− animals is significant. (B) Immunoblots of markers for cardiac remodeling in WT, Slc22a5+/+ Acadl−/− and Slc22a5jvs/+ Acadl−/− animals (5 male mice per group). Each lane contains 50 μg of total heart protein. The last lane of the BNP and MYH7 immunoblots includes a sample from a TAC mouse heart as positive control. The MYH7 band in the TAC sample was observed in 3 independent immunoblots, whereas all other samples were repeatedly negative. For each separate blot the α-Tubulin loading control is displayed. The position of the molecular weight markers is indicated in kDa. Quantification of relative protein levels did not reveal any differences between the Slc22a5+/+ Acadl−/− and Slc22a5jvs/+ Acadl−/− animals.

Article Snippet: Proteins were separated on Bolt® 4–12% or 8% Bis-Tris Plus gels (Invitrogen, Thermo Fisher Scientific Inc.), blotted onto a nitrocellulose membrane and detected using the following primary antibodies: BNP (1:500, bs-2207R) from Bioss antibodies (Woburn, MA), LCAD (1:2,000, 17256–1-AP) from Proteintech (Rosemont, IL), α-SMA (1:1,000, 19245) from Cell Signaling Technology (Danvers, MA), and α-tubulin (1:2,000, 32–2500) from Invitrogen, Thermo Fisher Scientific Inc.

Techniques: Western Blot, Positive Control, Molecular Weight